LDL/HDL Ratio in Cardiovascular Risk Assessment
Primary Treatment Target: LDL Cholesterol
- The European Society of Cardiology recommends LDL cholesterol as the primary target for cardiovascular risk assessment and treatment because nearly all lipid-lowering trials have used LDL-C as the indicator of treatment response, with a robust evidence base for LDL reduction improving cardiovascular outcomes 1, 2
- Every 1.0 mmol/L (40 mg/dL) reduction in LDL-C produces dose-dependent reductions in cardiovascular disease, as confirmed by the Cholesterol Treatment Trialists' Collaboration meta-analysis involving over 170,000 patients, with a strong level of evidence 1
- The European Society of Cardiology/European Atherosclerosis Society guidelines state that "TC and LDL-C remain the primary targets recommended in these guidelines" because most risk estimation systems and virtually all drug trials are based on these traditional measures, providing a high level of evidence 2
Role of the LDL/HDL Ratio in Risk Assessment
- The LDL/HDL ratio provides additional risk stratification beyond LDL alone, particularly for identifying patients who may be at higher risk despite seemingly acceptable LDL levels, with moderate evidence 1, 3
- The ratio makes intuitive sense by combining an atherogenic lipoprotein variable (LDL) with a protective one (HDL), and has been well-supported by observational epidemiology, with a moderate level of evidence 3
Critical Limitation: Not a Treatment Target
- The LDL/HDL ratio should be used as a marker of increased risk rather than as an index of treatment success or a therapeutic goal, with strong evidence from the European guidelines 1, 3
- European guidelines acknowledge that ratios are "useful for risk estimation, but for diagnosis and as treatment targets the components of the ratio have to be considered separately", providing a high level of evidence 1
Practical Clinical Algorithm
- For risk assessment, measure total cholesterol and HDL cholesterol, and calculate LDL cholesterol and the LDL/HDL or TC/HDL ratio for additional risk stratification, with moderate evidence 1, 2, 4
- For treatment decisions, focus therapeutic interventions on lowering LDL cholesterol, as this has the strongest evidence for reducing cardiovascular events, with high evidence 1, 2
LDL/HDL Ratio as a Cardiovascular Risk Marker
Definition and Calculation
- The LDL/HDL cholesterol ratio combines measurements of "bad" cholesterol (LDL) with "good" cholesterol (HDL) to provide a single risk assessment value, making intuitive sense as it combines an atherogenic lipoprotein variable (LDL) with a protective one (HDL) 5, 6
- The LDL/HDL ratio is calculated by dividing LDL cholesterol by HDL cholesterol, with higher ratios indicating greater coronary heart disease risk 5, 6
Clinical Significance for Risk Assessment
- The total cholesterol/HDL ratio is often used interchangeably with LDL/HDL ratio in clinical practice 5, 6
Important Clinical Caveats
- While the LDL/HDL ratio is valuable for risk assessment, it is not established as a treatment goal, according to European guidelines 7, 8, 9
- European guidelines acknowledge that low HDL cholesterol may rival high LDL cholesterol as a risk factor for coronary heart disease, but there is insufficient evidence to use HDL as a therapeutic target 7, 8, 9
- The ratio should be used as a marker of increased risk rather than necessarily as an index of treatment success 5, 6
Interpretation and Application
- The ratio must be interpreted as part of a complete lipid profile, not in isolation 10
- Even with a favorable ratio, elevated absolute LDL cholesterol levels still warrant appropriate management according to risk category 10
- Consider other cardiovascular risk factors including hypertension, diabetes, smoking, and family history 10
- The American College of Cardiology recommends focusing on absolute LDL cholesterol targets based on overall cardiovascular risk category rather than ratio targets, with targets including LDL <100 mg/dL for very high risk, LDL <130 mg/dL for high risk, and LDL <160 mg/dL for moderate risk 11